Boston, Massachusetts, United States, April 2025 – Intrinsic Therapeutics, a medical technology company revolutionizing care for lumbar discectomy patients, has announced the appointment of Keith Valentine as its new President and Chief Executive Officer, effective early May. He will also join the company’s Board of Directors.
Mr. Valentine brings over 30 years of leadership and commercialization experience within the spine and orthopedics industry. His notable tenure includes senior executive roles at Medtronic Spine and Biologics, NuVasive—where he served as President from 2004 to 2015—and SeaSpine, where he led as CEO through its merger with Orthofix until 2023.
“After enjoying decades in and around spinal fusion procedures, I’m incredibly excited to lead a dedicated and experienced team that will passionately transform conservative spine care,” said Keith Valentine, President and CEO, Intrinsic Therapeutics. “Intrinsic has the opportunity to meaningfully improve the early spine care continuum and enable a collaborative partnership with spine clinicians for the best patient outcomes. This is a blue-ocean market opportunity that only the Intrinsic Team gets to define and expand.”
Ryan Drant, Chairman of the Board, Intrinsic Therapeutics, added, “We are thrilled to welcome Keith Valentine as Intrinsic’s new Chief Executive Officer. Keith has a demonstrated track record of generating outstanding growth commercializing innovative spinal implants in his previous senior roles at NuVasive and SeaSpine. With Barricaid’s CPT-1 code becoming effective in January 2026, Keith brings the right combination of energy, leadership skills and spine industry experience to maximize the Barricaid opportunity and help hundreds of thousands of patients annually avoid unnecessary disc reherniations and related surgeries.”
He continued, “On behalf of the Intrinsic board I also want to thank Cary Hagan for his leadership, strategic thinking and exceptional determination over more than a decade while leading the company through the achievement of important milestones including Barricaid’s PMA approval and the granting of a CPT-1 code.”
About Barricaid
Barricaid is a proprietary annular closure device designed to prevent disc reherniation and reduce the need for repeat surgeries in patients with large annular defects after lumbar discectomy. The device has been implanted in over 11,000 patients and is supported by clinical evidence across eight patient populations, including two randomized controlled trials. A five-year multicenter level I RCT was published in JAMA, demonstrating its superior outcomes over discectomy alone. A Category 1 CPT Code for Bone Anchored Annular Closure—including Barricaid—has been approved and will be effective from January 1, 2026.
Read Also : HR Is Not a Support Function—It’s the CEO’s Most Powerful Growth Engine
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
From Gatekeeping to Gateway Building: Transforming How Organisations Create Access
Leadership In Talent Management: A Powerful Driver for Economic Growth
